^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
golcadomide (CC-99282)
i
Other names: CC-99282, BMS-986369, BMS986369, CC99282, BMS 986369, CC 99282
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
Cereblon modulator, CRL4-CRBN E3 ubiquitin ligase modulator
Related drugs:
1m
CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
1m
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. (PubMed, Blood Cancer Discov)
Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD® agent lenalidomide in preclinical models. Pharmacological and CRISPR screening further revealed genes and pathways underlying golcadomide's antitumor efficacy. These findings supported golcadomide as a promising drug candidate for DLBCL, providing a strong rationale for future golcadomide-based regimens.
Journal
|
IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
|
lenalidomide • golcadomide (CC-99282)
4ms
TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov)
P2, N=40, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Recruiting --> Active, not recruiting
Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive • LDH elevation
|
Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)
4ms
FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov)
P2, N=47, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • golcadomide (CC-99282)
4ms
Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro. (PubMed, J Med Virol)
Cereblon-binding immunomodulators (CBIs), such as pomalidomide (Pom), show in vitro efficacy and clinical activity against certain of these lymphomas. Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents...The novel CBIs had relatively little activity in Pom-resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.
Preclinical • Journal
|
CRBN (Cereblon) • ICAM1 (Intercellular adhesion molecule 1) • IRF4 (Interferon regulatory factor 4) • CD86 (CD86 Molecule)
|
pomalidomide • iberdomide (CC-220) • golcadomide (CC-99282)
4ms
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov)
P3, N=400, Recruiting, Celgene | Not yet recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
4ms
CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov)
P1/2, N=438, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Feb 2028 | Trial primary completion date: Apr 2026 --> Apr 2027
Enrollment closed • Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • Ezharmia (valemetostat) • Monjuvi (tafasitamab-cxix) • golcadomide (CC-99282)
5ms
EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=565, Recruiting, Genmab | Phase classification: P1/2 --> P2
Phase classification • Adverse events
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
5ms
CC-220-DLBCL-001: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (clinicaltrials.gov)
P1, N=174, Recruiting, Celgene | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2027 --> Dec 2028
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq) • iberdomide (CC-220) • golcadomide (CC-99282)
6ms
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov)
P1/2, N=49, Not yet recruiting, The Lymphoma Academic Research Organisation
New P1/2 trial
|
azacitidine • golcadomide (CC-99282) • roginolisib (IOA-244)
6ms
EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=565, Recruiting, Genmab | Phase classification: P2 --> P1/2
Phase classification • Adverse events
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
6ms
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov)
P3, N=400, Not yet recruiting, Celgene | Trial primary completion date: Jul 2030 --> Apr 2028
Trial primary completion date
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
Share via
